Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Liver Cancer Diagnostics Market Size, Value And Growth Trajectory Through 2030
The liver cancer diagnostics market size has demonstrated significant growth over recent years. It is forecast to expand from $10.32 billion in 2025 to $11.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This expansion in prior periods is attributable to factors such as the increasing prevalence of chronic liver diseases, a rising incidence of hepatocellular carcinoma, the expansion of hospital diagnostic infrastructure, growing awareness regarding early cancer screening, and advancements in imaging and pathology techniques.
The liver cancer diagnostics market is projected to experience substantial expansion over the upcoming years. By 2030, its valuation is anticipated to reach $14.75 billion, progressing at a compound annual growth rate (CAGR) of 7.4%. Several factors are driving this market’s expansion during the projected timeframe, including the wider acceptance of precision oncology diagnostics, an escalating need for non-invasive diagnostic approaches, the broadened scope of molecular testing capabilities, increased funding in oncology research, and the expanding implementation of AI-assisted diagnostic platforms. Key developments expected within this period involve the greater uptake of sophisticated molecular diagnostic tests, the increased application of imaging-based tools for early detection, the deepening integration of biomarker-based screening techniques, the broader availability of personalized oncology diagnostics, and a heightened emphasis on identifying cancer in its initial stages.
Get A Free Sample Report With In-Depth Market Insights:
Liver Cancer Diagnostics Market Development Factors: What’s Supporting Demand?
The increasing incidence of liver cancer is anticipated to fuel the expansion of the liver cancer diagnostics market moving forward. Liver cancer describes a condition where liver cells grow and multiply uncontrollably, leading to a life-threatening disease. Liver cancer diagnostic tests are performed following a diagnosis of primary carcinoma of the liver to determine if cancer cells are spreading within or around the liver, thus, the rising prevalence of liver cancer boosts the liver cancer diagnostics market. For instance, in January 2023, the Cancer Facts & Figures 2023 report from the American Cancer Society, a US-based voluntary health organization, revealed that new cases of liver and intrahepatic bile duct cancer in US females reached 13,230 in 2023. Furthermore, in 2023, an estimated 41,210 new cases of liver cancer were diagnosed in the US, with 29,380 people projected to die. Consequently, the increasing occurrence of liver cancer is driving the growth of the liver cancer diagnostic market.
Liver Cancer Diagnostics Market Segment Performance And Emerging Opportunities
The liver cancer diagnostics market covered in this report is segmented –
1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma
2) By Screening: Laboratory Testing, Imaging, Biopsy, Other Screenings
3) By Technology: Fluorescent In Situ Hybridization (FISH), Immunohistochemical (IHC), Other Technologies
4) By End Use: Hospitals And Diagnostic Laboratories, Academic And Research Institutes
Subsegments:
1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma, Advanced-Stage Hepatocellular Carcinoma
2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma
3) By Hepatoblastoma: Pure Hepatoblastoma, Mixed Hepatoblastoma
Liver Cancer Diagnostics Market Transformation Trends: What Innovations Are Driving Change?
Major companies active within the liver cancer diagnostics market are creating sophisticated biomarker-based assays and algorithms with the goal of enhancing diagnostic precision and aiding in early disease identification. These biomarker-based assays and algorithms are defined as diagnostic instruments that utilize specific biological indicators to identify illnesses, offering more accurate and efficient diagnostic capabilities. An illustration of this is Roche Diagnostics, a US-based biotech corporation, which introduced the Elecsys PIVKA-II assay and the Elecsys GAAD algorithm in November 2023. The Elecsys PIVKA-II assay identifies elevated levels of the PIVKA-II biomarker, which is linked to hepatocellular carcinoma (HCC), thereby improving the early detection of liver cancer in patients at high risk. Furthermore, the Elecsys GAAD algorithm consolidates several diagnostic markers, including PIVKA-II and AFP, to boost diagnostic accuracy and simplify decision-making processes in the detection of liver cancer.
Liver Cancer Diagnostics Market Leading Companies And Competitive Benchmarking
Major companies operating in the liver cancer diagnostics market are Abbott Laboratories, F Hoffmann La Roche Ltd, Qiagen NV, Thermo Fisher Scientific Inc, Siemens Healthineers, Illumina Inc, Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc, Danaher Corporation, Foundation Medicine Inc, Agilent Technologies Inc, Genemed Biotechnologies Inc, Merck KGaA, Fujifilm Medical Systems USA Inc, GE Healthcare, Advanced Cell Diagnostics Inc, Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon AS, BioGenex Laboratories Inc, OncoCyte Corporation, Guardant Health Inc, Exact Sciences Corporation, Grail Inc, Freenome Holdings Inc, Natera Inc, Personal Genome Diagnostics Inc, Thrive Earlier Detection Corp
View The Full Liver Cancer Diagnostics Market Report:
Liver Cancer Diagnostics Market Top Region By Revenue And Market Share
North America was the largest region in the liver cancer diagnostics market in 2025. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.